Dosage-dependent copy number gains in E2f1 and E2f3 drive hepatocellular carcinoma

• Main Authors: Kent, L.N, Bae, S, Tsai, S.-Y, Tang, X, Srivastava, A, Koivisto, C, Martin, C.K, Ridolfi, E, Miller, G.C, Zorko, S.M, Plevris, E, Hadjiyannis, Y, Perez, M, Nolan, E, Kladney, R, Westendorp, B, De Bruin, A, Fernandez, S, Rosol, T.J, Pohar, K.S, Pipas, J.M, Leone, G
• Other Authors: PHYSIOLOGY
• Format: Article
• Published: American Society for Clinical Investigation 2020
• Subjects: transcription factor E2F1; transcription factor E2F3; transcriptome; E2f1 protein, mouse; E2f3 protein, mouse; tumor protein; animal model; animal tissue; Article; cancer incidence; cancer prognosis; cancer survival; chromatin; chromatin immunoprecipitation; controlled study; copy number variation; disease course; DNA microarray; e2f1 gene; e2f3 gene; epigenetics; female; gain of function mutation; gene; gene dosage; gene expression; gene locus; gene mapping; gene mutation; genetic gain; genetic transcription; genetic variability; histopathology; human; human cell; immunoblotting; immunohistochemistry; liver cell carcinoma; male; mouse; mutation rate; nonhuman; polymerase chain reaction; protein expression; tumor volume; animal; genetics; knockout mouse; liver tumor; metabolism; tumor gene; Animals; Carcinoma, Hepatocellular; E2F1 Transcription Factor; E2F3 Transcription Factor; Gene Dosage; Genes, Neoplasm; Humans; Liver Neoplasms; Mice; Mice, Knockout; Neoplasm Proteins
• Online Access: https://scholarbank.nus.edu.sg/handle/10635/179227
• Institution: National University of Singapore

10.1172/JCI87583